Cambridge Biostability, a developer of temperature-stable liquid vaccines, agreed a joint venture with Panacea Biotec of India.
Joint venture
Cambridge Biostability Ltd (CBL), a developer of temperature-stable liquid vaccines, agreed a joint venture with Panacea Biotec Ltd, the second-largest vaccine producer in India, under which Panacea Biotec has taken a 10 per cent stake in CBL for £1.935 million.
Panacea gets the right to use CBL’s technology to develop a stable version of pentavalent and other combination vaccines for the treatment of diptheria, tetanus, pertussis (whooping cough), hepatitis B and haemophilus influenza B, which will not require storage under refrigeration or reconstitution before use.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
